Genmab — September 2017
-
Varslet om de gode aktiemarkeder flugter meget godt meldingen i foråret fra Lars Tvede´s investeringsrådgiver. " Vi står muligvis ved opkørslen til et 4-årigt langt bullmarked", eller noget i den retning udtalte investeringsrådgiveren. Jeg tænker, at en person som Lars Tvede nok vælger investeringsrådgiver fra øverste hylde.
-
http://ir.genmab.com//eventdetail.cfm?eventid=182189 Link til Morgan Stanley
-
det skulle jeg mene
-
så er der lidt musik hos mig
-
så kører vi
-
tisotumab 50% pts with activity 32% clinical respons
-
best data i past 20 years
-
næste år resultater for 6 yderligere typer cancer
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind